abaloparatide vs ibandronate
Side-by-side comparison of abaloparatide and ibandronate Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Tymlos
Boniva
Tymlos is a medicine to treat osteoporosis. It helps make your bones stronger and less likely to break.
Ibandronate (Boniva) is a medicine that helps treat and prevent bone loss in women after menopause. It makes bones stronger and less likely to break.
Tymlos treats osteoporosis in women after menopause and in men. It is for people who have a high chance of breaking a bone. This includes those who have already had a bone break due to osteoporosis or have other risk factors. It can also be used if other osteoporosis treatments did not work or could not be tolerated.
Ibandronate is used to treat and prevent osteoporosis in women after menopause. Osteoporosis is a condition that makes bones weak and more likely to break. This medicine helps to increase bone strength and reduce the chance of fractures, especially in the spine.
Tymlos is similar to a natural hormone in your body. It helps your body build new bone. This makes your bones stronger and less likely to break.
Ibandronate belongs to a class of drugs called bisphosphonates. It works by slowing down the breakdown of bone. This helps to increase bone density and reduce the risk of fractures.
- • High calcium in your urine
- • Feeling dizzy
- • Feeling sick to your stomach
- • Headache
- • Feeling your heart beat fast or irregularly
- • Back pain
- • Upset stomach
- • Pain in arms or legs
- • Diarrhea
- • Headache
- Headache 4,180
- Feeling sick to your stomach 3,222
- Feeling dizzy 3,122
- Feeling tired 2,742
- Increased heart rate 2,139
- Joint pain 243
- Diarrhea 230
- Feeling sick to your stomach 219
- Broken thigh bone 216
- Headache 198
Tymlos may increase the risk of bone cancer (osteosarcoma). You should not take this medicine if you have certain conditions that increase this risk. These include Paget's disease, bone cancer, radiation treatment to your bones, or certain hereditary disorders. If you have symptoms of feeling dizzy, palpitations, tachycardia, or nausea, you should sit or lie down.
This medicine can cause problems with your esophagus. To help prevent this, follow the directions carefully and stay upright for at least 60 minutes after taking it. Rarely, serious bone, joint, or muscle pain can occur. Tell your doctor if you have new pain in your thigh or groin. Osteonecrosis of the jaw (bone damage in the jaw) has been reported.
Tymlos is not for women who could get pregnant. It is not known if Tymlos can harm an unborn baby or pass into breast milk.
Ibandronate is not for use in women who can get pregnant. It is not known if this medicine will harm an unborn baby. Talk to your doctor if you are breastfeeding.
Also Compare — Nearby Drugs
Compare ibandronate with
How to Read This abaloparatide vs ibandronate Comparison
abaloparatide is classified in the PTHrP Analog drug class, while ibandronate sits within the Bisphosphonate class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, abaloparatide has 15,405 submissions while ibandronate has 1,106. Those figures reflect cumulative reporting volume — not per-patient risk — so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot substitute for clinical judgment. Effectiveness, tolerability, drug-drug interactions with your other medications, kidney and liver function, pregnancy status, insurance formulary, and price all feed into a decision that only a licensed prescriber can make responsibly. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This page is for educational purposes only, is not medical advice, and should not be used to self-switch between abaloparatide and ibandronate — always consult your physician or pharmacist first.
Important: This comparison is for informational purposes only. Drug effects vary between individuals. Always consult your doctor or pharmacist for personalized medical advice.